Malignant melanoma employs multifaceted strategies to evade immune surveillance, including upregulation of the PD-L1/PD-1 axis, where tumor cell-derived PD-L1 binds PD-1 on T cells to suppress their activation and effector functions. Here, CD274 is linked to neoplasm.